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We report a 51-year-old woman with known SLE on low dose prednisone, recently started on
rituximab, who presents with acute respiratory failure and bilateral air space disease. After
an initial treatment with broad spectrum antibiotics for healthcare-associated pneumonia
and negative serologic studies, a diagnosis of pneumocystis pneumonia was established using
bronchoalveolar lavage. We suggest that rituximab can be an aggravating cause of pneumocys-
tis in patients treated with prednisone.
Published by Elsevier Ltd.Case report
A 51-year-old female known to have systemic lupus eryth-
ematosus (SLE) with secondary chronic kidney disease was
admitted to our hospital with a one week history of
shortness of breath, fever, headache, cough and night
sweats. The patient was diagnosed with SLE one year prior
and was maintained on prednisone 20 mg daily. She was
recently started on rituximab and had a total of four
weekly doses for a suspected flare up of lupus nephritis.
She received the last dose four weeks prior to presenta-
tion. On hospital admission, the patient was in mild respi-
ratory distress. Body temperature was 102.9 F, respiratory
rate was 20 breaths per minute, and pulse oxygen satura-
tion was 84% while breathing room air. Blood pressure wasC.A. Hage).
td.138/72 mmHg and heart rate was 103 beats per minute.
Physical examination revealed coarse bilateral inspiratory
crackles.
Laboratory findings were as follows: White blood cell
count was 6.6 103 cells/mL with a manual differential
showing 80% neutrophils and 13% lymphocytes. Hemoglobin
concentration was 10.7 g/dL, and platelet count was
235 103/mL. Serum chemistries showed a creatinine level
of 4.3 mg/dL, BUN of 49 mg/dL, serum sodium of
129 mmol/L, potassium of 5.8 mmol/L, serum bicarbonate
of 20 mmol/L, chloride of 100 mmol/L, LDH was 695 units/
L. Admission chest radiograph showed bibasilar air space
disease (Fig. 1A). Chest CT revealed diffuse bilateral ground
glass opacities with more confluent airspace consolidation
in the lung bases (Fig. 1B).
The patient was admitted to the hospital and was
treated for healthcare-associated pneumonia (HCAP) with
vancomycin, cefepime and ciprofloxacin. Workup done
including blood and urine cultures, urine Histoplasma
Figure 1 (A): Chest radiograph showing bibasilar interstitial
infiltrates. (B): chest CT scan showing bilateral patchy areas of
groundglass opacities with airspace consolidation in the right
lung bases, and scattered, small nodular opacities.
PCP and Rituximab 135and Legionella antigens, CMV titers, and HIV antibody
screen were all negative. Absolute CD4 blood count was
70 cells/mL.
Despite two days of broad spectrum antibiotics, the
patient continued to be febrile and had worsening hypoxia
and increased work of breathing. Bronchoscopy for a bron-
choalveolar lavage (BAL) was performed. Cytopathologic
examination of BAL smears revealed Pneumocystis jiroveci.
No other pathogenic organisms were isolated. The patient
was started on Trimethoprim/Sulfamethoxazole and the
steroid dose was increased. Her condition subsequently
improved as fever and hypoxia resolved and she recovered
completely and was discharged from the hospital. CD4
count recovered spontaneously after discontinuation of
rituximab. Six months later her absolute CD4 count was
539 cells/mL.Discussion
P. jiroveci pneumonia (PCP) is the most common opportu-
nistic infection in AIDS patients. Less frequently, PCP is
seen in non-HIV immunosupressed patients with hemato-
logic malignancies, organ transplantation, inflammatory
disorders, and solid tumors.1
Our patient has SLE. She had a negative HIV antibody
screen. Both humoral and cellular arms of her immune
system are suppressed, since she was on prednisone and
rituximab. Rituximab is a monoclonal antibody that selec-
tively targets and depletes CD20þ B lymphocytes. B-cell
depletion affects antibody production, antigen presenta-
tion and T cell activation. SLE treatment with rituximab has
been shown to affect both the cellular and humoral
immune response.2
The temporal relationship between rituximab infusion
and the development of PCP suggest that rituximab pre-
disposed our patient to pneumocytis infection. Rituximab
has been proposed as a risk factor for PCP infection. The
mechanism leading to infection is not clear. In one case
series, one of three patients with refractory pemphigus
vulgaris who were treated with rituximab developed fatal
pneumocystis pneumonia 4 months after finishing
therapy.3 In a recent study, the incidence of PCP was
13 % in a population of 46 lymphoma patients who
received rituximab-CHOEP-14 chemotherapy.4,5 Rituximab
can also cause profound CD4 depletion. Patients with HIV-
associated NHL had a moderate reduction in their CD4 cell
count after 6 cycles of treatment with chemotherapy and
rituximab.6 In addition, chronic use of corticosteroids is
a known risk factor for PCP in non-AIDS patients. Other
opportunistic infections such as CMV retinitis, pulmonary
tuberculosis, salmonellosis and cryptosporidiosis have been
reported in patients receiving rituximab.
In conclusion, we suggest that the combination of rit-
uximab and systemic corticosteroids steroid predisposed
our patient to pneumocystis infection. Further studies are
needed to better define this association and determine
whether PCP prophylaxis is indicated in those who receive
rituximab.
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